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Abstract
Adrenocortical carcinosarcoma is an extremely rare and aggressive variant of adrenocortical carcinoma character-
ized by the presence of both carcinomatous and sarcomatous components, with the latter often showing hetero-
logous differentiation. Due to the rarity and unusual histology, it may pose a diagnostic challenge. In order to
increase awareness and identify potential diagnostic pitfalls, we report the ninth case of non-functioning adreno-
cortical carcinosarcoma in a 45-year-old man who presented with worsening epigastric pain and a left large retro-
peritoneal mass in close proximity to the body/tail of pancreas and third portion of the duodenum with
displacement of the kidney without parenchymal invasion and multiple liver nodules detected by computed tomo-
graphic scan. On en bloc resection, the tumor grossly did not involve the pancreas, kidney or colon. Histologically,
the tumor was composed of two distinct components - an epithelioid component with granular cytoplasm that
stained for synaptophysin, Melan-A, calretinin, and vimentin compatible with adrenocortical differentiation, and a
pleomorphic to spindled component that was positive for desmin and myogenin, compatible with rhabdomyosar-
comatous differentiation. A wedge biopsy of a liver nodule showed morphologic features similar to the epithelial
component of the primary tumor. The patient died three months after surgery due to locoregional and distant
recurrence. Adrenocortical carcinosarcoma is a rare malignancy that adds to the differential diagnostic considera-
tions for a retroperitoneal epithelioid malignancy. Awareness of this as a possibility will help in distinguishing this
tumor from other carcinomas, melanomas, and true sarcomas.
Background
Adrenocortical carcinoma is a rare but highly aggressive
malignancy with an estimated annual incidence of
between 1.5 to 2 per million population [1]. Women are
more commonly affected. There is a bimodal age distri-
bution with cases a peak occurring before age 5 years
and a second in the fourth to fifth decades [2]. The
prognosis is poor with a significant proportion (21% to
3 9 % )o fp a t i e n th a v i n gd i s t a n tm e t a s t a s i sa tt h et i m eo f
presentation [2,3] and a 5 year overall survival ranges
between 38% to 60% [1]. Even after an apparently cura-
tive resection, the majority of patients develop early
tumor recurrence or distant metastasis [1-3].
Carcinosarcomas are defined as malignant neoplasms
showing both epithelial and mesenchymal differentiation
with heterologous features including rhabdomyoblastic,
chondroid, or osteogenic differentiation [4]. We report a
case of primary adrenal carcinosarcoma and review the
literature to raise awareness of this extremely rare var-
iant of adrenal carcinoma with worse prognosis present-
ing high differential diagnosis difficulties.
Case Presentation
Case History
A 45 year-old African American male with no past med-
ical history of hypertension or prior malignancy was
admitted to the hospital with worsening epigastric pain,
low-grade fever, nausea, vomiting, decreased appetite,
and 9 kg loss of weight over three months. On physical
examination, his blood pressure was 189/119 mm Hg.
His abdomen was mildly distended. A dynamic, con-
trast-enhanced abdominal computed tomography scan
revealed a large (19 × 15 cm) irregularly and peripher-
ally enhancing predominantly necrotic left retroperito-
neal mass in close proximity to the body/tail of
pancreas and third portion of the duodenum with dis-
placement of the kidney without parenchymal invasion
(Fig 1). Extensive bilobar hepatic metastatic lesions were
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laboratory studies did not show significant steroid hor-
mone or catecholamine excess. No other mass lesions
were noted in the patient.
An en-bloc resection of the mass which included a left
radical nephrectomy, splenectomy, distal pancreatect-
omy, left partial colectomy, and wedge biopsy of one of
the hepatic lesions were performed. However, despite
this, at 3 months, the patient had a locoregional recur-
rence and progression of liver disease. Due to his poor
performance status (Eastern Cooperative Oncology
Group performance status 3), no chemotherapy was per-
formed. The patient died 3 months after the surgery.
Autopsy was not performed.
Gross Examination
The gross specimen consisted of a centrally necrotic,
peripherally viable appearing, heterogenous gray to
pink-yellow friable suprarenal mass, 17.0 × 6.0 × 6.0 cm,
2974 grams, completely effacing the adrenal gland (Fig.
2A). Pancreas and kidney were adherent to tumor but
otherwise uninvolved by tumor (Fig 2B). Spleen and
colon were uninvolved by tumor.
Microscopic Examination
The tumor showed extensive necrosis (over 70%). Two
components were noted, an epithelioid component,
and a pleomorphic/spindled component. The epithe-
lioid component consisted of sheet and nests of loosely
cohesive polygonal cells with clear and eosinophilic
cytoplasm resembling adrenocortical cells (Fig. 3A).
These cells showed highly atypical nuclei and large
eosinophilic nucleoli (Fuhrman’s grade III) with high
mitotic activity (average of seven mitoses per 10 high-
power fields). The pleomorphic/spindled component,
comprising approximately 75% of viable tumor, showed
predominantly spindle-shaped cells arranged in fasci-
cular pattern with highly pleomorphic nuclei with
dense irregularly clumped chromatin and prominent
d e n s ee o s i n o p h i l i cn u c l e o l i (Fig. 3B) and occasional
anaplastic multinucleated neoplastic giant cells. Also
identified in these areas were large elongated or ovoid
cells with abundant deeply eosinophilic cytoplasm and
eccentrically located nuclei and prominent nucleoli,
suggestive of rhabdomyosarcomatous differentiation
(Fig. 3C). The mitotic count in these areas was even
higher (30 mitoses/10 high-power fields).
Histologically as well, there was no involvement of
the pancreas, kidney, or colon, and the surrounding
adipose tissue was unremarkable. The liver wedge
biopsy showed a tumor nodule morphologically identi-
cal to the epithelioid component of the retroperitoneal
tumor.
Figure 1 CT scan of adrenocortical carcinosarcoma. Necrotic left
adrenal mass in close proximity to the body/tail of pancreas and
third portion of the duodenum with displacement of the kidney
Figure 2 Adrenocortical carcinosarcoma gross appearance. A. Tumor adherent to pancreas (arrow) without apparent parenchymal
involvement. B. Tumor compressing the adjacent left kidney (arrow) without parenchymal involvement.
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An extensive immunohistochemical panel was per-
formed to evaluate both epithelioid and pleomorphic
spindled components of tumor (Table 1). The epithe-
lioid component was strongly and diffusely positive for
vimentin, synaptophysin (Fig. 4A), and Melan-A (Fig.
4B) and focally positive for calretinin (Fig. 4C). The
pleomorphic/spindled component was strongly and dif-
fusely positive for vimentin, focally strongly positive
for synaptophysin, Melan-A, and focally weakly posi-
tive for calretinin. The cells resembling rhabdomyo-
blasts were immunoreactive for smooth muscle
markers, desmin (Fig. 4D), myogenin, and myoglobin.
Immunohistochemical stains for AE1/AE3, S-100,
HMB-45, tyrosinase, inhibin, PLAP, CD99, and chro-
mogranin were negative in both carcinomatous and
sarcomatous components.
Based on the histologic and immunohistochemical
profile, the tumor was diagnosed as an adrenocortical
carcinosarcoma.
Discussion
Adrenocortical carcinoma containing a component of
sarcoma or sarcoma-like (spindle cell) differentiation is
extremely rare, with only 8 prior cases described [5-12].
According to WHO classification 2004 in other epithe-
lial malignant neoplasms, these tumors are classified as
sarcomatoid carcinoma. Within the broad category of
sarcomatoid carcinoma, tumors with histological areas
of both carcinoma and sarcoma containing differentiated
sarcomatous elements, such as malignant cartilage, bone
or skeletal muscle are subclassified as carcinosarcoma.
To our knowledge, only 3 prior cases of carcinosarcoma
have been reported [7-9].
Figure 3 Adrenocortical carcinosarcoma histological appearance. A. Carcinomatous component showing epithelioid cells with clear to
eosinophilic cytoplasm arranged in nested pattern (40×). B. Sarcomatous component composed of uniform spindle cells arranged in a fascicular
pattern (40×). C. Sarcomatous component showing elongated or ovoid rhabdomyoblastic tumor cells with eccentrically located nuclei and
deeply eosinophilic cytoplasm (20×).
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Stain Carcinomatous component Sarcomatous component Company Clone Dilution
AE1/AE3 Negative Negative Dako AE1/AE3 1:100
Vimentin Positive Positive Ventana V9 Prediluted
Desmin Negative Positive Ventana DE-R-11 Prediluted
Myogenin Negative Weakly Positive Cell Marque F5D Prediluted
Myoglobin Negative Positive Ventana Polyclonal Prediluted
S-100 Negative Negative Dako Polyclonal 1:500
HMB-45 Negative Negative Ventana HMB45 Prediluted
Tyrosinase Negative Negative Vector T311 1:75
Melan-A Focally
weakly positive
focally positive Dako A103 1:100
Synaptophysin Positive focally positive Dako Cell Marque Prediluted
Chromogranin Negative Negative Ventana LIK2H10 Prediluted
Inhibin Alpha Negative Negative Dako R1 1:50
PLAP Negative Negative Biogenex PL8/F6 1:400
CD99 Negative Negative Dako 12E7 1:75
Calretinin Positive Focally positive Invitrogen Polyclonal 1:100
Figure 4 Adrenocortical carcinosarcoma immunohistochemistry. A. The carcinomatous areas are strongly positive for synaptophysin (40×). B.
Melan-A shows patchy positivity in the carcinomatous areas (40×). C. Calretinin immunostain showing diffuse cytoplasmic and nuclear positivity
in carcinomatous areas (40×). D. Desmin immunostaining highlighting rhabomyoblastic cells in sarcomatous area (40×).
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sarcomatoid carcinomas, including our patient, are sum-
marized in Table 2. The 9 patients ranged from ages 29
to 79 with a mean age of 53, which appears similar to
conventional adrenocortical carcinoma (mean age 40-50
years old). Although most studies of conventional adre-
nocortical carcinoma have a female preponderance [2],
sarcomatoid carcinoma show nearly equal distribution
of two sexes. Initial clinical presentation is most often
flank/abdominal pain or discomfort (six of 9 cases).
Tumors tend to be very large at the time of initial pre-
sentation (mean size 13.0 cm, weight 1113 grams). Two
of 9 (22%) tumors were functional with production of
dehydroepiandrosterone sulfate or aldosterone. All nine
cases were treated with surgical resection often com-
bined with systemic adjuvant chemotherapy, however,
all patients died within 1 year (mean postoperative sur-
vival 5 months). Including our case, only four of 9
tumors (44%) were actually carcinosarcomas most often
with rhabdomyosarcoma (3/4) followed by mixture of
osteosarcoma and chondrosarcoma (1/4). Though diffi-
cult to say based on small numbers, adrenocortical car-
cinosarcomas and other sarcomatoid carcinomas
without heterologous elements show similar distribution
of age (mean age 48.7 versus 56.2), tumor size (13.3 cm
vs. 12.8 cm), and outcome (mean survival: 6 months vs.
5.4 months).
Radiographically and even grossly, it is often difficult to
confirm adrenal origin for these tumors due to the
advanced presentation. Indeed, in two of 9 cases of sarco-
matoid carcinoma, imaging studies could not correctly
locate the adrenal origin of tumor. As such, the differential
diagnostic considerations include other aggressive
retroperitoneal malignancies including other carcinomas,
particularly renal cell carcinoma, true sarcoma, large cell
lymphoma, and metastases. Although some adrenocortical
neoplasms produce steroid hormones, others are non-
functional, which makes it difficult to identify specific
adrenocortical tumor markers. In our case, hormone levels
were unremarkable. Here, a thorough clinical history and
precise characterization of structures involved may be use-
ful in narrowing possibilities. In our case for instance, the
pancreas, and kidney on thorough examination were
grossly uninvolved arguing against these as primary sites
of origin. There was no lymphadenopathy arguing against
lymphoma, and there was no history of a prior malignancy
or any other masses arguing against a metastasis.
The diagnosis of adrenocortical carcinosarcoma on his-
tologic examination is often challenging as well. It requires
thorough sampling of the specimen to confirm the bipha-
sic pattern and identify a well differentiated carcinomatous
component allowing to prove the adrenal origin as well as
to rule out retroperitoneal sarcoma or poorly differen-
tiated carcinoma.
The adrenal phenotype of this tumor was verified by the
immunopositivity for a panel of immunohistochemical
markers, namely, Melan-A [13], synaptophysin [14], calre-
tinin [15], particularly on the well differentiated carcino-
matous component. Of note, in contrast to most
carcinomas, adrenocortical carcinomas are notoriously
negative or only focally weakly positive for cytokeratins. In
this study, we showed that sarcomatous component of the
tumor also focally retains positivity for Melan-A, synapto-
physin and calretinin, supporting the notion that sarcoma-
tous area of the tumor has indeed originated from the
adrenocortical carcinoma rather than representing a
Table 2 Clinicopathologic features of adrenocortical sarcomatoid carcinoma
Author Age Sex Clinical
Presentation
Endocrine
dysfunction
Size (cm) weight
(g)
Sarcomatous component postoperative time of
death
Okazumi et al.
(1987)
46 M Abdominal
distention
No 14 cm,
880 g
Spindle 6 months
Collina et al.
(1989)
68 F Abdominal
discomfort
No 11 cm Spindle 6 months
Decorato et al.
(1990)
42 F Abdominal pain No 19 cm,
1400 g
Rhabdomyosarcoma 7 months
Fischer et al.
(1992)
29 F Virilization, weight
loss
Yes 12.5 cm, 610 g Rhabdomyosarcoma 8 months
Barksdale et al.
(1993)
79 F hypertension Yes 5 cm,
199 g
Osteosarcoma,
chondrosarcoma
NA
Lee et al. (1997) 61 M Flank pain No 12 cm Spindle 2 days
Sturm et al.
(2008)
31 M Abdominal pain No 12 cm,
620 g
Spindle 3 months
Coli et al.
(2010)
75 F Abdominal pain No 15 cm Spindle 12 months
This study 45 M Abdominal pain No 17 cm,
2974 g
rhabdomyosarcoma 3 months
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case contains frequent foci of rhabdomyoblastic cells.
These foci could be sharply highlighted by desmin, myo-
genin and myoglobin, which is both a sensitive and speci-
fic marker for myogenic differentiation [16].
Similar to the clinicoradiographic diagnostic considera-
tions, the histologic differential diagnostic considerations
include 3 basic categories - other carcinosarcomas from
other sites, most notably sarcomatoid renal cell carci-
noma, true primary retroperitoneal soft tissue tumor, and
metastases with sarcomatoid elements such as a germ
cell tumor or rarely melanoma. Sarcomatoid renal cell
carcinoma or hepatocellular carcinoma with sarcomatoid
dedifferentiation both may show morphologically similar
appearance with clear and eosinophilic cytoplasm.
However, positive staining of CD56, inhibin, Melan-A,
synaptophysin, calretinin and negative staining of pan-
cytokeratin, EMA, Hepar-1 in adrenocortical sarcomatoid
carcinoma may be of help in the differential diagnosis
[17,18]. A primary retroperitoneal sarcoma such as lipo-
sarcoma, rhabdomyosarcoma, or malignant peripheral
nerve sheet tumor also needs to be excluded by careful
histological and immunohistochemical analysis. The lack
of well-differentiated liposarcomatous component and
presence of well-differentiated adrenocortical carcinoma
component excludes the possibility of de-differentiated
liposarcoma. In difficult cases, immunohistochemical,
fluorescence in situ hybridization or quantitative PCR
analysis for CDK4 and MDM2 status may be of interest
[19]. Rhabdomyosarcoma is usually a neoplasm of chil-
dren/infants and lacks well-differentiated adrenocortical
carcinoma component. Malignant peripheral nerve sheet
tumor with rhabdomyoblastic elements (Triton tumor)
can be excluded by morphology as well as negativity of
Melan-A, synaptophysin, and calretinin and positivity of
S-100 [20,21].
Metastatic melanoma with heterologous elements might
enter the differential diagnosis since this will also be posi-
tive for Melan-A and negative for cytokeratin. This can be
distinguished from an adrenocortical tumor by positivity
for other melanocytic makers such as S-100, HMB-45, tyr-
osinase and negativity of calretinin, synaptophysin and
inhibin [22]. It is of note, however, that Coli et al. reported
unusual positive staining of S-100 and HMB-45 in adreno-
cortical sarcomatoid carcinoma, which has not been
reported previously for adrenocortical tumors. Although
they interpreted this immunohistochemical pattern as
aberrant melanocytic differentiation, further studies may
be needed to confirm this unusual expression of S-100
and HMB-45. Mixed germ cell tumor, most often metasta-
sis from testicular primary, with somatic teratomatous
malignancy (rhabdomyosarcoma) can be excluded by posi-
tive staining of PLAP and cytokeratins and negative stain-
ing of vimentin, Melan-A and calretinin [23].
Together, based on our literature review, carcinoma-
tous component of adrenocortical sarcomatoid carci-
noma is immunoreactive for Melan-A (2 of 3 cases,
67%), synaptophysin (2 of 4 cases, 50%), calretinin (2
of 4 cases, 50%), inhibin (1 of 3 cases, 33%), vimentin
(5 of 5 cases, 100%), Neuron-specific enolase (NSE) (2
of 2 cases, 100%), occasionally positive for AE1/AE3 (1
of 5 cases, 20%), and negative for chromogranin (0 of
3c a s e s ,0 % ) ,E M A( 0o f2c a s e s ,0 % ) ,a n dn e u r o f i l a -
ment (0 of 2 cases, 0%). Sarcomatous component is
positive for desmin (4 of 4 cases, 100%), myogenin (2
o f2c a s e s ,1 0 0 % ) ,H H F 3 5( 2o f2c a s e s ,1 0 0 % ) ,v i m e n -
tin (6 of 6 cases, 100%), myoglobin (1 of 1 case, 100%),
caldesmon (1 of 1 case, 100%), smooth muscle actin (1
of 2 cases, 50%), calretinin (1 of 2 cases, 50%), Melan-
A (1 of 3 cases, 33%), occasionally synaptophysin (1 of
4 cases, 25%) and negative for AE1/AE3 (0 of 5 cases,
0%), EMA (0 of 2 cases, 0%), HMB-45 (0 of 2 cases,
0 % ) ,i n h i b i n( 0o f3c a s e s ,0 % ) ,c h r o m o g r a n i n( 0o f3
cases, 0%).
Conclusion
In conclusion, we have reported the ninth case of adre-
nocortical sarcomatoid carcinoma with rhabdomyoblas-
tic differentiation (carcinosarcoma). This lesion is often
difficult to distinguish from other retroperitoneal neo-
plasms by radiographic imaging and is a highly aggres-
sive form of adrenocortical malignancy. Thorough
sampling, careful histological examination and widely
extensive immunohistochemical investigation are often
necessary to confirm adrenocortical origin and distin-
guish this tumor from other retroperitoneal sarcomatoid
neoplasms.
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